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ABSTRACT 
A new series of 6,8-halo-substituted-2H-[1,2,4]triazino[5,6-b]indole-3(5H)-one/-thione and 
6,8-halo-substituted 5-methyl-2H-[1,2,4]triazino[5,6-b]indol-3(5H)-one/-thione (5a-5l) were 
designed and synthesized keeping in view of the structural requirement of pharmacophore. 
The above compounds were characterized by thin layer chromatography and spectral analysis. 
Anticonvulsant activity of the synthesized compounds was evaluated by the maximal electro-
shock (MES) test. Neurotoxicity and CNS depressant effects were evaluated by the rotarod 
motor impairment and Porsolt’s force swim tests, respectively. A computational study was 
carried out, for calculation of pharmacophore pattern, prediction of pharmacokinetic proper-
ties and toxicity properties. The above study revealed that the compounds 8-chloro-2H-
[1,2,4]triazino[5,6-b]indol-3(5H)-one (5e), 6,8-dibromo-2H-[1,2,4]triazino[5,6-b]indol-
3(5H)-one (5i) and 6,8-dibromo-5-methyl-2H-[1,2,4]triazino[5,6-b]indol-3(5H)-one (5k) pos-
sess excellent anticonvulsant activity in the series with little CNS depressant effect and no 
neurotoxicity as compared to standard drugs phenytoin and carbamazepine. 
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INTRODUCTION 
Epilepsy is a heterogeneous group of 
disorders characterized by the neuronal hy-
perexcitability and hypersynchronous neu-
ronal firing presented with episodes of sen-
sory, motor or autonomic phenomenon with 
or without loss of consciousness (Stafstrom, 
2006). The cellular mechanism of human 
epilepsy is still uncertain and hence the pre-
sent drug therapy is rather concerned only 
with control of epilepsy symptoms than 
cure (Kenda et al., 2004). Epilepsy is one of 
the most common disorders of the brain, 
affecting 60 million people worldwide ac-
cording to epidemiological studies (Husain 
et al., 2010; Scheurer and Pedley, 1990). 
Every year approximately 250,000 new 
cases are added to this figure (Husain et al., 
2009). Now there are more than 40 differ-
ent anti-epileptic drugs (AEDs) in clinical 
use, but still about 30 % of patients contin-
ue to experience uncontrolled seizures, and 
they are pharmaco-resistant to the available 
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therapy (Picot et al., 2008). Further, today’s 
treatment for seizures requires continuous 
medication for a long period, which is in 
turn associated with many adverse effects, 
such as nausea, ataxia, drowsiness, gastro-
intestinal disturbance, hyperplasia, anaemia 
etc. (Naithani et al., 2010). 
It is observed that most of the antiepi-
leptic drugs, which are in clinical use are 
neither linked with any particular site of 
action nor with a known mechanism of ac-
tion (Bialer et al., 2010). Many AEDs ex-
hibit their potency via many possible mech-
anisms of action. The lack of understanding 
and complexity in mechanism of action cer-
tainly affect the development of new candi-
dates as possible AEDs through mecha-
nism-driven designs. So, presently the an-
tiepileptic research mainly focuses on in-
vestigation of new anticonvulsant agents 
through conventional screening and struc-
tural modifications rather than mechanism 
based drug design. Therefore, drug identifi-
cation is usually conducted via in vivo 
screening tests on the basis of seizure type 
rather than etiology. Anticonvulsant activity 
is mainly attributed to the presence of aryl 
binding site with aryl/alkyl hydrophobic 
group, hydrogen bonding domain and elec-
tron donor group, which are the essential 
requirements for the molecules to show po-
tential activity as proposed by Dimmock et 
al. (2000a, b). Pandeya et al. (2002) have 
suggested a new pharmacophore model for 
semicarbazones displaying anticonvulsant 
activity (Figure 1). Proposed pharmaco-
phore model contains four binding sites for 
interaction with a macromolecular complex 
in vivo. 
1. An aryl hydrophobic binding site (A) 
with halogen substituent preferably at para 
position 
2. A hydrogen bonding domain (HBD) 
3. An electron donor group (D) 
4. Another hydrophobic-hydrophilic site 
controlling the pharmacokinetic properties 
of the anticonvulsant (C). 
(A) (HBD)
(D)
(C)
Figure 1: Suggested pharmacophore model for 
designed triazines displaying anticonvulsant 
activity 
 
These new aspects might be useful for 
designing prototypic molecules with poten-
tial anticonvulsant activity (Figure 2). 
Lamotrigine, a phenyl-1,2,4-triazine an-
alog is used as anticonvulsant agent and in 
the treatment of bipolar disorder. Lamotri-
gine acts by prolonging inactivation of 
voltage-sensitive Na+ channels and suppres-
sion of high frequency firing. It may also 
directly block voltage sensitive Na+ chan-
nels by stabilizing the presynaptic mem-
brane and preventing release of excitatory 
neurotransmitters, mainly glutamate and 
aspartate (Taylor, 1996; Tripathi, 2010). 3-
(4-Chloro-phenylimino)-5-methyl-1,3-dihy-
dro-indol-2-one showed 87 % protection at 
100 mg kg-1 with an ED50 value of 
53.61 mg kg-1 in the metrazol-induced con-
vulsion model. This new agent was less 
neurotoxic than phenytoin, and showed 
greater protection against maximal electro-
shock method and metrazol-induced con-
vulsion models than standard drug (Sodium 
Valproate) (Sridhar et al., 2002). Replace-
ment of hydrogen (from -NH in indole nu-
cleus) by methyl group enhanced the lipo-
philicity of the compounds (Smitha et al., 
2008). Aryl semicarbazones and 4-(Aryl-
oxy) phenyl semicarbazones showed potent 
anticonvulsant activity in the MES screen-
ing (Dimmock et al., 1995; Wang et al., 
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1998). Several investigations have recog-
nized aryl thiosemicarbazones as structural-
ly novel class of anticonvulsants (Karki et 
al., 2009; Kshirsagar et al., 2009; Ragab et 
al., 2010). 
Intrigued by the above observations, 
and in an attempt to design and develop 
new potential anticonvulsant agents, a hy-
brid pharmacophoric approach was adopted 
in which the 1,2,4-triazine, indole and 
semicarbazone or thiosemicarbazone nucle-
us were hybridized in one structure hoping 
to synergize the anticonvulsant potential of 
these nucleus (explained diagrammatically 
in Figure 3). The validity of this design was 
assessed through anticonvulsant screening 
of the target compounds. 
Chemistry 
The reaction sequence leading to the 
synthesis of titled compounds (5a-l) is 
shown in Scheme 1. All chemicals and sol-
vents for synthesis were supplied by Spec-
trochem chemicals (India) and S.D. Fine 
Chemicals (India). Synthesized compounds 
were purified by recrystallized and column 
chromatography. The progress of reaction 
was monitored by Silica gel-GF coated 
aluminum plate using iodine vapors or UV 
light as visualizing agents. Developing solvent 
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Figure 2: Structures of proposed general pharmacophore model of the synthesized compound and 
reported chemical drugs 
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Figure 3: Rational concept to new 6,8-halo substituted-2H-[1,2,4]triazino[5,6-b]indole-3(5H)-one/-
thione and 6,8-halo-substituted 5-methyl-2H-[1,2,4]triazino[5,6-b]indol-3(5H)-one/-thione (5a-l) 
 
 
for TLC was ethyl acetate and n-hexane 
(50 %). The melting points of newly syn-
thesized compounds were determined by 
digital melting point apparatus and are un-
corrected. IR (KBr) spectra of the synthe-
sized compounds were on a Nicolet 5PC 
FTIR spectrophotometer (λ-max in cm-1) 
and 1H NMR spectra were recorded on a 
Brucker Model-300 NMR Spectrometer in 
DMSO-d6 using tetramethylsilane (TMS) as 
the internal reference (chemical shifts in δ 
ppm). Chemical shifts are reported in ppm 
downfield from tetramethylsilane (TMS). 
The physical characterization data of the 
synthesized compounds are given in Table 
1. 
Pharmacology 
Anticonvulsant screening 
The anticonvulsant evaluation of the 
synthesized compounds (5a-l) was per-
formed using reported procedures (Krall et 
al., 1978; Porter et al., 1984). Male albino 
mice (CF-1 strain, 18-25 g) were used as 
experimental animal. The synthesized com-
pounds were suspended in polyethylene 
glycol (PEG-400). All experimental proto-
cols were carried out with permission from 
the Institutional Animal Ethics Committee 
(IAEC). Animals were obtained from the 
Central Animal House Facility, Dr. K. N. 
Modi Institute of Pharmaceutical Education 
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and Research, Modinagar, Ghaziabad, Uttar 
Pradesh, India. 
 
Maximal electroshock seizure method 
(MES) 
Anticonvulsant activity of titled com-
pounds 5a-l was measured by maximal 
electroshock seizure (MES) test following 
the methods of Krall et al. (1978) and Por-
ter et al. (1984). For all tests based on MES 
convulsions, 60 Hz of alternating current 
(50 mA) was delivered for 0.2 s by elec-
trodes which had been primed with an elec-
trolyte solution containing an anaesthetic 
agent (0.5 % tetracaine HCl). In prelimi-
nary screening, titled compounds were ad-
ministered intraperitoneal in volume 
0.01 mL/kg body weight at the dose of 30, 
100, 300 mg/kg and anticonvulsant activity 
was assessed after 0.5 and 4 h intervals ad-
ministration. Abolition of the hind limb ton-
ic extensor spasm was recorded as a meas-
urement of anticonvulsant activity. 
 
Neurotoxicity screening 
Motor impairment of all synthesized 
compounds (5a-l) was measured in mice by 
the rotarod test (Dunham and Miya, 1957). 
The mice were trained to stay on an accel-
erating rotarod (INCO, Ambala, India) that 
rotated at six revolutions per minute. The 
rod diameter is 3.2 cm. Motor impairment 
was indicated by the inability of the animal 
to maintain equilibrium on the rod for at 
least 1 min in each of the trials.  
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Scheme 1: Synthesis of 6,8-halo-substituted-2H-[1,2,4]triazino[5,6-b]indole-3(5H)-one/-thione and 
6,8-halo-substituted 5-methyl-2H-[1,2,4]triazino[5,6-b]indol-3(5H)-one/-thione derivatives 
EXCLI Journal 2014;13:225-240 – ISSN 1611-2156 
Received: December 31, 2013, accepted: February 16, 2014, published: March 10, 2014 
 
 
230 
Table 1: Physical data of synthesized compounds 5a-l 
Code No. R1 R2 R3 X Molecular 
formula 
Rf % yield M.P. (0C)# 
5a F H H O C9H5FN4O 0.56 45 261-64 
5b F H H S C9H5FN4S 0.39 48 274-77 
5c F H CH3 O C10H7FN4O 0.58 52 253-56 
5d F H CH3 S C10H7FN4S 0.49 56 267-70 
5e Cl H H O C9H5ClN4O 0.43 56 209-12 
5f Cl H H S C9H5ClN4S 0.31 61 238-41 
5g Cl H CH3 O C10H7ClN4O 0.41 56 > 300 
5h Cl H CH3 S C10H7ClN4S 0.33 63 > 300 
5i Br Br H O C9H4Br2N4O 0.34 65 > 300 
5j Br Br H S C9H4Br2N4S 0.27 67 > 300 
5k Br Br CH3 O C10H6Br2N4O 0.52 59 > 300 
5l Br Br CH3 S C10H6Br2N4S 0.30 64 > 300 
* TLC solvent was ethyl acetate: n-hexane=50 % 
 
 
CNS depression study 
The CNS depression study of synthe-
sized compounds is performed by the 
forced swim model (Porsolt’s swim pool 
test) (Porsolt et al., 1978). Albino mice 
were placed in a chamber (diameter 45 cm, 
height 20 cm) containing water up to a 
height of 15 cm at 25 ± 2 °C. Two swim 
sessions were conducted, an initial 15 min 
pre-test, followed by a 5 min test session 24 
h later. The animals were administered with 
an i.p. injection (100 mg/kg) of the test 
compounds 30 min before the test session. 
The period of immobility (passive floating 
without struggling, making only those 
movements which were necessary to keep 
its head above the surface of water) during 
the 5 min test period were measured. 
Computational study  
Calculation of physicochemical parameters  
A computational study of titled com-
pounds (5a-l) was performed for prediction 
of ADME properties. Polar surface area 
(TPSA) (Ertl et al., 2000), milog P, number 
of rotatable bonds, molecular volume, 
number of hydrogen donor and acceptor 
atoms and violations of Lipinski’s rule of 
five (Lipinski et al., 2001) were calculated 
using Molinspiration online property calcu-
lation toolkit (Molinspiration, 2013). Ab-
sorption (% ABS) was calculated by: % 
ABS =109-(0.345×TPSA) (Zhao et al., 
2002). The druglikeness, drugscore and 
theoretical toxicity risks (mutagenic, tumor-
igenic, irritant and reproductive effects) 
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were also calculated using Osiris Property 
Explorer (http://www.organic-chemistry.org).  
 
RESULTS AND DISCUSSION  
Anticonvulsant and CNS depressant  
activities 
The newly synthesized 6,8-halo substi-
tuted-2H-[1,2,4]triazino[5,6-b]indole-3(5H) 
-one/-thione and 6,8-halo-substituted 5-
methyl-2H-[1,2,4]triazino[5,6-b]indol-3(5H) 
-one/-thione compounds 5a-l were subject-
ed to anticonvulsant screening by using 
standard model MES (Maximal Electro-
shock Seizure test) for their ability to re-
duce seizure spread (Table 2). Motor im-
pairment screening of the synthesized com-
pounds was also carried out by rotarod test 
and CNS depressant effect of the com-
pounds was determined by Porsolt’s force 
swim pool model. The anticonvulsant activ-
ity was tested after 0.5 and 4.0 h time inter-
vals at doses of 30, 100, and 300 mg/kg 
body weight, after i.p. administration. The 
CNS depressant activity was studied at a 
dose level of 100 mg/kg body weight (Ta-
ble 3). Phenytoin and carbamazepine were 
used as standard drugs. 
The anticonvulsant data of titled com-
pounds (5a-l) was summarized in Table 2, 
compounds 5a and 5b showed protection at 
maximum dose level of 300 mg/kg after 0.5 
and 4.0 h. Both compounds were found to 
be inactive at dose levels of 30 and 
100 mg/kg. Compound 5c displayed protec-
tion at maximum dose level (300 mg/kg) 
after 0.5 h. Compounds 5f, 5g, and 5j ex-
hibited activity at a dose level of 100 mg/kg 
after 0.5 h. These compounds were found to 
be inactive at 30 mg/kg dose. Compound 5i 
containing R1=R2=Br, R3=H, X=O groups, 
showed protection against induced seizures 
at lower dose level (30 mg/kg) after 4.0 h. 
Compound 5k reflected protection at 100 
and 300 mg/kg after 0.5 and 4.0 h. This 
compound was inactive at the dose level of 
30 mg/kg after 0.5 and 4.0 h. Compounds 
5d, 5h and 5l were inactive at all dose lev-
els (30, 100 and 300 mg/kg) after 0.5 and 
4.0 h. Compound 5e having R1=Cl, R2=H, 
R3=H, X=O groups, was found to be most 
active of the series showing activity both at 
100 mg/kg and 30 mg/kg after 0.5 and 4.0 
h. The neurotoxicity screening data re-
vealed that both compounds 5a and 5f hav-
ing R1=F, R2=H, R3=H, X=O and R1=Cl, 
R2=H, R3=H, X=S substitutions respective-
ly, displayed neurotoxicity at a dose level 
of 300 mg/kg after 4.0 h, whereas the rest 
compounds were without any neurotoxicity. 
Some selected compounds (5e, 5i and 
5k) exhibiting significant anticonvulsant 
activity were also tested for their CNS de-
pressant activity. These compounds showed 
54.39, 37.68 and 45.96 % increase in im-
mobility time with respect to control where 
as standard drug carbamazepine showed 
58.63 % increase in the immobility time 
(Table 3). Thus CNS depressant screening 
data showed that compounds 5i and 5k hav-
ing R1=R2=Br, R3=H, X=O and R1=R2=Br, 
R3=CH3, X=O groups respectively, exhibit-
ed less CNS depressant activity in compari-
son to carbamazepine. Compound 5e con-
taining R1=Cl, R2=H, R3=H and X=O 
groups, showed approximate equal CNS 
depressant activity in comparison to car-
bamazepine. The most active compound of 
this series was found to be 5e as it was ef-
fective in both 0.5 and 4.0 h time interval at 
dose levels of 100 and 30 mg/kg showing 
no motor impairment effect. The compound 
5e also showed approximate equal CNS de-
pressant activity in comparison to standard 
drug carbamazepine. The activity may be 
due to the presence of chloro (R1=Cl) and 
oxo (X=O) groups that provide adequate 
lipophilicity and well fitted to receptor site.  
Using the putative binding site theory 
proposed by Dimmock et al. (2000a, b) 
subsequently used by others (Gibson et al., 
2009; Pandeya et al., 2002) in postulating 
the interaction of anticonvulsant com-
pounds at a specific binding site, the mole-
cule observed to interact with the protein 
receptor as shown in Figure 4. 
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Table 2: Anticonvulsant and motor impairment screening of synthesized titled compounds (5a-l) using 
maximal electroshock seizure (MES) and rotarod models 
Code No. R1 R2 R3 X MESa Motor Impt.a 
0.5h 4.0h 0.5 h 4.0 h 
5a F H H O 300 300 - 300 
5b F H H S 300 300 - - 
5c F H CH3 O 300 - - - 
5d F H CH3 S - - - - 
5e Cl H H O 100 30 - - 
5f Cl H H S 100 - - 300 
5g Cl H CH3 O 100 - - - 
5h Cl H CH3 S - - - - 
5i Br Br H O - 30 - - 
5j Br Br H S 100 - - - 
5k Br Br CH3 O 100 300 - - 
5l Br Br CH3 S - - - - 
Control - - - - 
Phenytoinb 30 30 100 100 
Carbamazepineb 30 100 100 300 
a Doses of 30, 100, and 300 mg/kg were administered to albino mice through intraperitoneal (i.p.) route. The figures in the table 
indicate the minimum dose whereby bioactivity was demonstrated in half or more of mice. The animals were examined 0.5 and 
4 h after the drug administration. The dash (-) indicates an absence of activity at maximum dose administered (300 mg/kg).  
b Data of Phenytoin and Carbamazepine were used as reference drugs and were obtained from the reference Dimmock et al. 
(1995) and White et al. (1995). 
 
 
 
Table 3: Data of CNS depressant activity of the selected compounds performed in mice using forced 
swim test 
Compound Duration of immobility (sec) 
(mean ± SEM) 
 % Increased of  
immobility 
5e 81.89 ± 3.12 54.39 
5i 73.03 ± 5.53 37.68 
5k 77.42 ± 2.82 45.96 
Carbamazepine 84.14 ± 1.33 58.63 
Control 53.04 ± 2.47 - 
The compounds were tested at a dose of 100 mg/kg (i.p. in PEG 400). Control animals were administered with PEG 400 (i.p.). 
Each value represents the mean ± SEM of six mice. The CNS depressant effect was compared with respect to standard drug.  
*p < 0.0001. Data was analyzed by unpaired student’s t test. 
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Prediction of ADME properties 
A computational study of titled com-
pounds (5a-l) was performed for prediction 
of ADME properties such as absorption (% 
ABS), polar surface area (TPSA), miLog P, 
number of rotatable bonds, and violations 
of Lipinski’s rule of five by using Molinspi-
ration online property calculation toolkit. 
Topological polar surface area (TPSA), i.e., 
surface belonging to polar atoms, is a de-
scriptor that was shown to correlate well 
with passive molecular transport through 
membranes and, therefore, allows predic-
tion of transport properties of drugs in the 
intestines and blood-brain barrier crossing 
(Ertl et al., 2000). The percentage of ab-
sorption (% ABS) was calculated using 
TPSA. From all these parameters, it can be 
observed that all titled compounds (5a-l) 
exhibited a great % ABS ranging from 
83.31 to 92.95 % (Table 4). None of the 
titled compounds violated Lipinski’s pa-
rameters and making them potentially 
promising agents for epilepsy therapy. 
Herein, we also calculated the druglike-
ness and drugscore values for some com-
pounds (5e, 5i and 5k) to analyze their 
overall potential to qualify for a drug in-
cluding the comparison with some drugs 
currently in use in therapy against epilepsy 
(i.e., phenytoin, lamotrigine and carbama-
zepine) (Table 5, Figure 5). The druglike-
ness value is calculated based on the occur-
rence frequency of every one of the frag-
ments of the analyzed molecules and com-
pared to commercial drugs and non-drug 
like compounds. In the Osiris program, the 
occurrence frequency of each fragment is 
determined within the collection created by 
shredering 3300 traded drugs as well as 
15,000 commercially available chemicals 
(Fluka) yielding a complete list of all avail-
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Figure 4: Proposed bind-
ing interactions of the title 
compounds using putative 
binding site theory (Dim-
mock et al., 2000a, b; Gib-
son et al., 2009; Pandeya 
et al., 2002). 
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Table 4: Pharmacokinetic parameters important for good oral bioavailability of titled compounds (5a-l) 
Code No. R1 R2 R3 X % ABS TPSA (A2) n-
ROTB 
MW MV miLogP n-OHNH 
donors 
n-ON 
acceptors 
Lipinski’s 
violations 
Rule     - - - <500 - <5 <5 <10 <1 
5a F H H O 83.319 74.437 0 204.164 157.600 0.332 2 5 0 
5b F H H S 89.208 57.366 0 220.232 166.478 0.675 2 4 0 
5c F H CH3 O 87.064 63.58 0 218.191 174.543 0.400 1 5 0 
5d F H CH3 S 92.954 46.509 0 234.259 183.421 0.742 1 4 0 
5e Cl H H O 83.319 74.437 0 220.619 166.205 1.819 2 5 0 
5f Cl H H S 89.208 57.366 0 236.687 175.083 2.162 2 4 0 
5g Br Br H O 83.319 74.437 0 343.966 188.44 2.688 2 5 0 
5h Br Br H S 89.208 57.366 0 360.034 197.318 3.030 2 4 0 
5i Cl H CH3 O 87.064 63.58 0 234.646 183.147 1.887 1 5 0 
5j Cl H CH3 S 92.954 46.509 0 250.714 192.025 2.230 1 4 0 
5k Br Br CH3 O 87.064 63.58 0 357.993 205.382 2.755 1 5 0 
5l Br Br CH3 S 92.954 46.509 0 374.061 214.26 3.098 1 4 0 
% ABS, percentage of absorption; TPSA, topological polar surface area; n-ROTB, number of rotatable bonds; MW, molecular weight; MV, molecular volume; n-OHNH, number of hydrogen bond 
donors; n-ON, number of hydrogen bond acceptors; miLogP, logarithm of compound partition coefficient between n-octanol and water 
 
 
Table 5: Druglikeness, drugscore and in silico toxicity risks of titled compounds 5e, 5i, 5k and standard drugs 
Code 
No. 
R1 R2 R3 X Druglikeness Drugscore Mutagenic Tumorigenic Irritant Reproductive 
Effective 
5e H Cl H O 2.38 0.50 3 1 1 1 
5i H Br Br O 3.85 0.71 1 1 1 1 
5k CH3 Br Br O 2.93 0.65 1 1 1 1 
Lamotrigine -0.88 0.51 1 1 1 1 
Phenytoin 4.20 0.87 1 1 1 1 
Carbamazepine 2.80 0.22 3 1 1 3 
Toxic (3), less toxic (2) and no toxicity (1) 
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able fragments. In this case, positive values 
point out that the molecule contains pre-
dominantly the better fragments, which are 
frequently present in commercial drugs but 
not in the non-druglike collection of Fluka 
compounds. The drugscore combines drug-
likeness, clogP, logS, molecular weight and 
toxicity risks in one handy value that may 
be used to judge the drug potential of a 
compound. Interestingly we noticed that the 
compounds (5e, 5i and 5k) with positive 
druglikeness (2.38-3.85) and drugscore 
(0.50-0.71) values were similar or even bet-
ter than some of the drugs currently used on 
the market (Table 5, Figure 5). 
Theoretical toxicity risks (mutagenic, 
tumorigenic, irritant and reproductive ef-
fects) were also calculated by Osiris pro-
gram. Only one compound 5e displayed 
mutagenic toxicity. Tumorigenic, irritant 
risks and reproductive effects were not re-
ported by compound 5e. Theoretical toxi-
city profile (mutagenic, tumorigenic, irrit-
ant and reproductive effective) of the 
compound 5i and 5k was found to be equal 
to that of the standard drugs Phenytoin and 
Lamotrigine (Table 5 and Figure 6). Theo-
retically no-toxicity profile of compounds 
5i and 5k reinforces further synthetic and 
Figure 5: Graph-
ical representa-
tion of Druglike-
ness and drug-
score values of 
compounds 5e, 
5i, 5k, lamotri-
gine, phenytoin 
and carbama-
zepine 
Figure 6: Graph-
ical representa-
tion of in silico 
toxicity risks of 
compounds 5e, 
5i, 5k, lamotrig-
ine, phenytoin 
and carbama-
zepine 
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pharmacological exploration for the devel-
opment of new anticonvulsant drugs. 
 
CONCLUSION 
In present study, the compounds (5a-l) 
were designed, synthesized, characterized 
and their anticonvulsant activity was evalu-
ated by using MES model. The compounds 
were also screened for neurotoxicity by us-
ing rotarod model and CNS depressant ac-
tivity by forced swim test. The some titled 
compounds displayed the significant anti-
convulsant activity with little or no neuro-
toxicity as compared to standard drug 
(phenytoin and carbamazepine). A compu-
tational study showed that none of the com-
pounds violated Lipinski’s parameters, 
hence making them potentially promising 
agent for epilepsy therapy. It was concluded 
that halogen substitution (i.e. F, Cl and Br) 
on the phenyl ring and thio group on 1,2,4-
triazine ring in compounds 5a-l increase the 
lipophilicity of compound that lead to grad-
ual augmentation of compounds’ ability to 
cross the blood brain barrier (BBB). Di-
bromo substitution on phenyl ring (i.e. Di-
bromophenyl) also increases the lipophilici-
ty of compound. Compounds 5e, 5i and 5k 
containing electron withdrawing groups 
(i.e. Cl, and Br), displayed excellent protec-
tion against MES model. Hence, these 
compounds may be regarded as a potential 
anticonvulsant candidate for further inves-
tigation. 
 
EXPERIMENTAL PROTOCOL   
Chemistry 
Synthesis of 5,7-Dibromoisatin 
Isatin (5.0 g, 34 mmol, 1 equiv) was 
warmed in ethanol (95 %, 100 mL) with 
stirring until it dissolved. Bromine (16.3 g, 
102 mmol, 5.2 mL, 3.0 equiv) was added 
dropwise to the stirred isatin solution whilst 
maintaining the temperature of the reaction 
mixture between 70-75 °C. The solution 
was cooled to room temperature and placed 
on ice for 30 min. The solid product was 
washed with water and cold ethanol and 
then recrystallized from ethanol to yield 
bright orange-red crystals of 5,7-dibromo-
isatin (60 %), mp 251-254 °C (lit. Vine et 
al., 2007, 248-250 °C). 
Synthesis of N-Methyl isatin derivatives 
To a suspension of (0.1 mol) of isatin 
derivatives, in 200 mL of anhydrous meth-
anol, 100 mL of 10 % methanolic potassi-
um hydroxide solution was added in por-
tions with stirring for 30 min. To this mix-
ture, 15 mL of dimethyl sulfate was added 
and after 1 h, the solution was filtered to 
remove potassium methyl sulfate. After re-
moval of about 250 mL of solvent under 
reduced pressure, 40 mL of warm water 
was added to the obtained residue. On cool-
ing, orange precipitate occurred which was 
filtered and dried to obtain N-Methyl isatin 
derivatives (Gupta et al., 2010). 
Synthesis of isatin semicarbazones or isatin 
thiosemicarbazones (3a-l) 
Semicarbazones and thiosemicarba-
zones (3a-l) were synthesized according to 
the procedure reported in literature (Hlavac 
et al., 2003; Aanandhi et al., 2008). Substi-
tuted isatin (1 mole) was dissolved in boil-
ing acetic acid in 100 mL beaker on hot 
plate. Semicarbazide hydrochloride 
(1 mole) was dissolved in distilled water 
(10 mL) in another 100 mL beaker. Then 
this solution was added in boiling isatin so-
lution. The mixture was boiled for 20-
30 min with stirring. After cooling, the sol-
id formed was filtered off, washed with 
acetic acid followed with water. The dried 
product was recrystallized from acetic acid 
affording yellow crystals.  
Substituted isatin (1 mole) was dis-
solved in boiling acetic acid (50 mL) in 
250 mL round bottom flask. Thiosemi-
carbazide (1 mole) was dissolved in di-
stilled water (10 mL) in 100 mL beaker. 
Then this solution was added in boiling isa-
tin solution. The mixture was refluxed for 
about 10 hours with stirring. After cooling 
the solid formed was filtered off, washed 
with acetic acid followed with water. The 
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dried product was recrystallized from etha-
nol-chloroform (50 %).  
Synthesis of 6-(2-amino-3,5-substituted 
phenyl)-1,2,4-triazines (4a-l) 
6-(2-Amino-3,5-substituted phenyl)-
1,2,4-triazines (4a-l) were synthesized ac-
cording to the procedure reported in litera-
ture (Hlavac et al., 2003). An appropriate 
isatin semicarbazone or isatin thiosemi-
carbazone (3a-l, 2.00 g) was dissolved in a 
boiling solution of sodium hydroxide (1 M, 
100 mL) in 250 mL conical flask. This mix-
ture was refluxed for 3-4 hours. The pro-
gress of reaction was monitored by alumi-
num coated TLC plate using 50 % ethyl ac-
etate and n-hexane solvent system. After 
completion of reaction, the mixture was 
cooled and then acidified with acetic acid. 
The solid formed was immediately filtered 
off, washed with water and dried. 
Synthesis of 6,8-halo- substituted-2H-
[1,2,4]triazino[5,6-b]indole-3(5H)-one/-
thione and 6,8-halo-substituted 5-methyl-
2H-[1,2,4]triazino[5,6-b]indol-3(5H)-one/-
thione (5a-l) 
Triazine derivatives (5a-l) were synthe-
sized according to the procedure reported in 
literature (Hlavac et al., 2003). An appro-
priate 6-(2-amino-3,5-substituted phenyl)-
1,2,4-triazine (4a-l, 4 mmol) was dissolved 
in acetic acid (100 mL) in 250 mL round 
bottom flask. The mixture was boiled. The 
progress of reaction was monitored by alu-
minum coated Merck TLC plate using 50 % 
ethyl acetate and n-hexane solvent system. 
After completion of reaction, the solid 
formed was filtered off, washed with water 
and dried. 
8-fluoro-2H-[1,2,4]triazino[5,6-b]indol-
3(5H)-one 5a 
IR (KBr): max = 3257 (NH), 1655 
(C=O, amide), 1601 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 7.41-7.42 (m, 3H, 
ArH), 11.60 (s, 1H, =N-NH), 12.72 (s, 1H, 
NH) ppm. Anal. calcd for C9H5FN4O : C 
52.95, H 2.47, N 27.44; found C 52.99, H 
2.52, N 27.40.  
 
8-fluoro-2H-[1,2,4]triazino[5,6-b]indole-
3(5H)-thione 5b 
IR (KBr): max = 3134 (NH), 1613 
(C=N), 1043 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) = 7.62-7.63 (m, 3H, 
ArH), 12.10 (s, 1H, NH), 12.83 (s, 1H, =N-
NHCS) ppm. Anal. calcd for C9H5FN4S : C 
49.08, H 2.29, N 25.44; found C 49.03, H 
2.34, N 25.48. 
8-fluoro-5-methyl-2H-[1,2,4]triazino[5,6-
b]indol-3(5H)-one 5c 
IR (KBr): max = 3178 (NH), 1663 
(C=O, amide), 1612 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 2.19 (s, 3H, N-
CH3), 7.51-7.53 (m, 3H, ArH), 13.04 (s, 
1H, =N-NH), ppm. Anal. calcd for 
C10H7FN4O : C 55.05, H 3.23, N 25.68; 
found C 55.09, H 3.28, N 25.72.  
8-fluoro-5-methyl-2H-[1,2,4]triazino[5,6-
b]indole-3(5H)-thione 5d 
IR (KBr): max = 3268 (NH), 1618 
(C=N), 1018 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) = 2.26 (s, 3H, N-CH3), 
7.50-7.55 (m, 3H, ArH), 12.82 (s, 1H, =N-
NHCS) ppm. Anal. calcd for C10H7FN4S : 
C 51.27, H 3.01, N 23.92; found C 51.31, H 
2.71, N 23.97.  
8-chloro-2H-[1,2,4]triazino[5,6-b]indol-
3(5H)-one 5e 
IR (KBr): max = 3321 (NH), 1650 
(C=O, amide), 1606 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 7.81-7.86 (m, 3H, 
ArH), 11.85 (s, 1H, =N-NH), 12.92 (s, 1H, 
NH), ppm. Anal. calcd for C9H5ClN4O : C 
49.00, H 2.28, N 25.40; found C 48.94, H 
2.36, N 25.34.  
8-chloro-2H-[1,2,4]triazino[5,6-b]indole-
3(5H)-thione 5f 
IR (KBr): max = 3298 (NH), 1615 
(C=N), 1070 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) =7.02-7.15 (m, 3H, 
ArH), 12.52 (s, 1H, NH), 12.86 (s, 1H, =N-
NHCS) ppm. Anal. calcd for C9H5ClN4S : 
C 45.67, H 2.13, N 23.67; found C 45.72, H 
2.19, N 23.63.  
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8-chloro-5-methyl-2H-[1,2,4]triazino[5,6-
b]indol-3(5H)-one 5g 
IR (KBr): max = 3328 (NH), 1679 
(C=O, amide), 1609 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 2.23 (s, 3H, N-
CH3), 7.68-7.77 (m, 3H, ArH), 11.65 (s, 
1H, =N-NH) ppm. Anal. calcd for 
C10H7ClN4O : C 51.19, H 3.01, N 23.88; 
found C 51.24, H 3.07, N 23.84. 
8-chloro-5-methyl-2H-[1,2,4]triazino[5,6-
b]indole-3(5H)-thione 5h 
IR (KBr): max = 3248 (NH), 1635 
(C=N), 1040 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) = 2.21 (s, 3H, N-CH3), 
7.50-7.78 (m, 3H, ArH), 12.89 (s, 1 H, =N-
NHCS) ppm. Anal. calcd for C10H7ClN4S : 
C 47.91, H 2.81, N 22.35; found C 47.97, H 
2.76, N 22.39  
6,8-dibromo-2H-[1,2,4]triazino[5,6-
b]indol-3(5H)-one 5i 
IR (KBr): max = 3317 (NH), 1659 
(C=O, amide), 1588 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 7.31 (d, 1H, J= 
8.1 Hz, ArH), 7.43 (d, 1H, J= 8.1 Hz, ArH), 
11.85 (s, 1H, =N-NH), 12.89 (s, 1H, NH) 
ppm. Anal. calcd for C9H4Br2N4O : C 
31.43, H 1.17, N 16.29; found C 31.37, H 
1.22, N 16.34.  
6,8-dibromo-2H-[1,2,4]triazino[5,6-
b]indole-3(5H)-thione 5j 
IR (KBr): max = 3286 (NH), 1622 
(C=N), 1046 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) = 7.36 (d, 1H, J= 7.5 Hz, 
ArH), 7.79 (d, 1H, J= 7.5 Hz, ArH), 11.79 
(s, 1H, NH), 13.12 (s, 1H, =N-NHCS) ppm. 
Anal. calcd for C9H4Br2N4S : C 30.02, H 
1.12, N 15.56; found C 29.95, H 1.15, N 
15.63 
6,8-dibromo-5-methyl-2H-
[1,2,4]triazino[5,6-b]indol-3(5H)-one 5k 
IR (KBr): max = 3271 (NH), 1661 
(C=O, amide), 1610 (C=N) cm-1. 1H NMR 
(300 MHZ, DMSO-d6) = 2.14 (s, 3H, N-
CH3), 7.27 (d, 1H, J= 7.8 Hz, ArH), 7.47 
(d, 1H, J= 7.8 Hz, ArH), 11.93 (s, 1H, =N-
NH) ppm. Anal. calcd for C10H6Br2N4O : C 
33.55, H 1.69, N 15.65; found C 33.59, H 
1.63, N 15.71.  
6,8-dibromo-5-methyl-2H-
[1,2,4]triazino[5,6-b]indole-3(5H)-thione 
5l 
IR (KBr): max = 3247 (NH), 1627 
(C=N), 1025 (C=S) cm-1. 1H NMR (300 
MHZ, DMSO-d6) = 2.26 (s, 3H, N-CH3), 
7.26 (d, 1H, J= 7.7 Hz, ArH), 7.68 (d, 1H, 
J= 7.7 Hz, ArH), 12.39 (s, 1H, C =N-
NHCS) ppm. Anal. calcd for C10H6Br2N4S : 
C 32.11, H 1.62, N 14.98; found C 32.06, H 
1.68, N 15.05. 
 
ACKNOWLEDGEMENTS 
Authors are thankful to Dr. K. N. Modi 
Institute of Pharmaceutical Education and 
Research, Modinagar, Ghaziabad, Uttar 
Pradesh, for providing research facilities. 
The authors are also really grateful to 
CDRI, Lucknow and IIT, New Delhi for 
providing the spectral analysis of the com-
pounds. 
 
REFERENCES 
Aanandhi MV, George S, Vaidhyalingam V. Syn-
thesis and antimicrobial activities of 1-(5-sub-
stituted-2-oxo indolin-3-ylidene)-4-(substituted pyr-
idin-2-yl)thiosemicarbazide. Arkivoc 2008;11:187-
94. 
Bialer M, Johannessen SI, Levy RH, Perucca E, 
Tomson T, White HS. Progress report on new an-
tiepileptic drugs: a summary of the Tenth Eilat Con-
ference (EILAT X). Epilepsy Res 2010;92:89-124. 
Dimmock JR, Pandeya SN, Quail JW, Pugazhenthi 
U, Allen TM, Kao GY et al. Evaluation of the semi-
carbazones, thiosemicarbazones and biscarbohydra-
zones of some aryl alicyclic ketones for anticonvul-
sant and other biological properties. Eur J Med 
Chem 1995;30:303-14. 
Dimmock JR, Vashishtha SC, Stables JP. Anticon-
vulsant properties of various acetylhydrazones, ox-
amoylhydrazones and semicarbazones derived from 
aromatic and unsaturated carbonyl compounds. Eur J 
Med Chem 2000a;35:241-8. 
Dimmock JR, Vashishtha SC, Stables JP. Ureylene 
anticonvulsants and related compounds. Pharmazie 
2000b;55:490-4. 
EXCLI Journal 2014;13:225-240 – ISSN 1611-2156 
Received: December 31, 2013, accepted: February 16, 2014, published: March 10, 2014 
 
 
239 
Dunham MS, Miya TA. A note on a simple appa-
ratus for detecting neurological deficit in rats and 
mice. J Am Pharm Assoc Sci 1957;46:208. 
Ertl P, Rohde B, Selzer P. Fast calculation of molec-
ular polar surface area as a sum of fragment-based 
contributions and its application to the prediction of 
drug transport properties. J Med Chem 2000;43: 
3714-7. 
Gibson A, Harkless J, Alexander M, Scott KR. 
Enaminones 10. Molecular modeling aspects of the 
5-methylcyclohexenone derivatives. Bioorg Med 
Chem 2009;17:5342-6. 
Gupta L, Sunduru N, Verma A, Srivastava S, Gupta 
S, Goyal N et al. Synthesis and biological evaluation 
of new [1,2,4]triazino[5,6-b] indol-3-ylthio-1,3,5-
triazines and [1,2,4]triazino[5,6-b]indol-3-ylthio-
pyrimidines against Leishmania donovani. Eur J 
Med Chem 2010;45:2359-65. 
Hlavac J, Buchtik R, Slouka J, Hradil P, Wieder-
mannova I. Synthesis of oxo analogs of Lamotrigine 
and related compounds. Arkivoc 2003;1:22-8. 
Husain A, Naseer MA, Sarafroz M. Synthesis and 
anticonvulsant activity of some novel fused hetero-
cyclic 1,2,4-triazolo-3,4-b-1,3,4-thiadiazole deriva-
tives. Acta Polo Pharm Drug Res 2009;66:135-40. 
Husain A, Rashid M, Akhter A, Mishra R, Gupta D. 
Design, synthesis and pharmacological activities of 
novel N-1-2-(substituted phenyl)-4-oxo-1,3-
thiazolan-3-yl-2,2-diphenyl-acetamides. Int J Pharm 
Sci Rev Res 2010;5:102-6. 
Karki SS, Bahaduria VS, Rana V, Kumar S, Subbaro 
PG, Das U et al. 1-Arylmethyl-2,3-dioxo-2,3-
dihydroindolethiosemicarbazones as leads for devel-
oping cytotoxins and anticonvulsants. J Enzyme 
Inhib Med Chem 2009;24:537-44. 
Kenda BM, Matagne AC, Talaga PE, Pasau PE, Dif-
ferding E, Lallemand BI et al. Discovery of 4-sub-
stituted pyrrolidone butanamides as new agents with 
significant antiepileptic activity. J Med Chem 2004; 
47:530-49. 
Krall RL, Penry JK, White BG, Kupferberg HJ, 
Swinyard EA. Antiepileptic drug development: II. 
Anticonvulsant drug screening. Epilepsia 1978;19: 
409-28. 
Kshirsagar A, Toraskar MP, Kulkarni VM, Dhana-
shire S, Kadam V. Microwave assisted synthesis of 
potential antiinfective and anticonvulsant thiosemi-
carbazones. Int J Chem Tech Res 2009;1:696-701. 
Lipinski CA, Lombardo L, Dominy BW, Feeney PJ. 
Experimental and computational approaches to esti-
mate solubility and permeability in drug discovery 
and development settings. Adv Drug Deliv Rev 
2001;46:3-26. 
Molinspiration Cheminformatics, Bratislava, Slovak 
Republic, Available from:  
http://www.molinspiration.com/services/properties.
html (accessed 23.09.13). 
Naithani M, Chopra S, Somani BL, Singh RK. Stud-
ies on adverse metabolic effects of antiepileptics and 
their correlation with blood components. Curr Opin 
Neurobiol 2010;1(2):117-20. 
Pandeya SN, Raja AS, Stables JP. Synthesis of isatin 
semicarbazones as novel anticonvulsants – role of 
hydrogen bonding. J Pharm Pharm Sci 2002;5:266-
71. 
Picot MC, Baldy-Moulinier M, Daurs JP, Dujols P, 
Crespel A. The prevalence of epilepsy and pharma-
coresistant epilepsy in adults: a population based 
study in a western European country. Epilepsia 
2008;49:1230-8.  
Porsolt RD, Anton G, Blanet N, Jalfer M. Behavior-
al despair in rats: a new model sensitive to antide-
pressant treatments. Eur J Pharmacol 1978;47:379-
86. 
Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, 
Kupferberg HJ, Scoville B et al. Antiepileptic drug 
development program. Cleveland Clin Q 1984;51: 
293-305. 
Ragab FA, Hassan GS, AbuYossef HA, Yahya TA, 
Abd El-Latif HA. Synthesis and anticonvulsant ac-
tivity of 4-oxo and 4-thioxo-8-bromobenzopyran 
derivatives. Arzneimittelforschung 2010;60:171-6. 
Scheurer ML, Pedley TA. The evaluation and treat-
ment of seizures. N Engl J Med 1990;323:1468-74. 
Smitha S, Pandeya SN, Stables JP, Ganapathy S. 
Anticonvulsant and sedative-hypnotic activities of 
N-acetyl/methyl isatin derivatives. Sci Pharm 
2008;76:621-36. 
Sridhar SK, Pandeya S, Stables JP, Ramesh A. Anti-
convulsant activity of hydrazones, Schiff and Man-
nich bases of isatin derivatives. Eur J Pharm Sci 
2002;16:129-32. 
Stafstrom CE. Epilepsy: A review of selected clini-
cal syndromes and advances in basic science. J 
Cereb Blood Flow Metab 2006;26:983-1004. 
EXCLI Journal 2014;13:225-240 – ISSN 1611-2156 
Received: December 31, 2013, accepted: February 16, 2014, published: March 10, 2014 
 
 
240 
Taylor CP. Voltage-gated Na+ channels as targets 
for anticonvulsant, analgesic and neuroprotective 
drugs. Curr Pharm Des 1996;2:375-9. 
Tripathi KD. Essentials of medical pharmacology. 
6th ed. Jaypee Brothers Medical Publishers (P) Ltd., 
2010. 
Vine KL, Locke JM, Ranson M, Benkendorff K, 
Pyne SG, Bremner JB. In vitro cytotoxicity evalua-
tion of some substituted isatin derivatives. Bioorg 
Med Chem 2007;15:931-8. 
Wang Y, Cai S, Lan N, Keana J, Ilyin V, Weber E. 
The use of carbocyclic and heterocyclic substituted 
semicarbazones and thiosemicarbazones as sodium 
channel blockers. PCT/US98/08004 1998;01-81. 
White HS, Woodhead JH, Franklin MR, Mattson 
RH, Meldrum BS. Antiepileptic drugs. 4th ed, 
(p 99). New York: Rave Press, 1995. 
Zhao YH, Abraham MH, Le J, Hersey A, Luscombe 
CN, Beck G et al. Rate-limited steps of human oral 
absorption and QSAR studies. Pharm Res 2002;19: 
1446-57. 
